Phathom Pharmaceuticals, Inc.
PHATPhathom Pharmaceuticals is a commercial-stage biopharmaceutical company dedicated to the development and commercialization of novel treatments for gastrointestinal diseases.
Earnings
Next report
Jul 30, 2026 (Tomorrow)Valuation & ratios
Segments
Competitors
By market cap
By revenue growth
By net margin
Profile
Phathom Pharmaceuticals is a commercial-stage biopharmaceutical company dedicated to the development and commercialization of novel treatments for gastrointestinal diseases. The company's core value proposition centers on vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB) that provides a potent and rapid alternative to traditional proton pump inhibitors. Their primary focus is addressing significant unmet needs in acid-related disorders such as GERD and H. pylori infections.
Phathom holds a first-mover advantage as the provider of the only FDA-approved PCAB in the United States, positioning it as a premium alternative to the established but often inadequate generic PPI market.
Questions, answered.
- What is Phathom Pharmaceuticals, Inc.'s market cap?
- Phathom Pharmaceuticals, Inc. (PHAT) has a market capitalization of $953.1M and trades on NASDAQ.
- What is Phathom Pharmaceuticals, Inc.'s revenue and profitability?
- Phathom Pharmaceuticals, Inc. generated $204.9M in trailing twelve-month revenue with a net loss of $157.3M, representing a net margin of -76.8%. Gross margin stands at 84.9%, with free cash flow of -$97.8M. These figures are based on the Q1 2026 filing.
- Who are Phathom Pharmaceuticals, Inc.'s competitors?
- Phathom Pharmaceuticals, Inc.'s key competitors include Vanda Pharmaceuticals Inc., Opko Health Inc., Scienture Holdings, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
- Who does Phathom Pharmaceuticals, Inc. partner with?
- Phathom Pharmaceuticals, Inc.'s notable partners include Takeda Pharmaceutical Company Limited, Evonik Operations GmbH, Catalent Pharma Solutions, LLC, and others.
- Where is Phathom Pharmaceuticals, Inc. headquartered?
- Phathom Pharmaceuticals, Inc. is headquartered in United States of America and employs approximately 112 people. It has been publicly traded since 2019.
